EMMA
Emmaus Life Sciences, Inc.
Key Financials
Gross Profit
$11.6M
↓ 25.0%
Revenue
$12.5M
↓ 25.2%
Operating Income
$231000
↑ 112.2%
Net Income
$-7492000
↓ 16.1%
Total Assets
$21.4M
↓ 9.2%
EPS (Diluted)
$-0.12
↓ 20.0%
Total Liabilities
$85.0M
↑ 6.2%
Shareholders' Equity
$-63608000.00
↓ 12.6%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 9/2/2026 | View on SEC |
| 8-K | 8/14/2026 | View on SEC |
| 10-Q | 8/14/2026 | View on SEC |
| 8-K | 5/15/2026 | View on SEC |
| 10-Q | 5/15/2026 | View on SEC |
| 3 | 4/21/2026 | View on SEC |
| 8-K | 4/17/2026 | View on SEC |
| 8-K | 4/14/2026 | View on SEC |
| 8-K | 3/31/2026 | View on SEC |
| 10-K | 3/31/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | EMMA |
| Company Name | Emmaus Life Sciences, Inc. |
| CIK | 822370 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 310-214-0065 |